Exchange: NASDAQ·Updated 05:07 PM EDT
News
all
press releases
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.
Zacks
Futures Flat Ahead Of Key PCE Report, Nvidia Earnings
Futures Flat Ahead Of Key PCE Report, Nvidia Earnings Stock futures are are flat and Treasuries slipped while oil stumbled heading into today's PCE report and NVDA earnings. As of 8:00am ET, S&P Futures are unchanged and Nasdaq futures drop 0.2% as?NVDA and MRVL both rise 0.2% with...
Zero Hedge
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?
Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.
Zacks
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.
Zacks
SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It?
Spyre's 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty valuation raises the stakes for upcoming readouts.
Zacks
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses
Spyre beats Q2 loss estimates as positive phase II pipeline progress and upcoming data readouts fuel investor optimism and lift the stock.
Zacks
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today
SYRE has surged on pipeline progress and a strong cash position, but with no product revenue and key trial data still ahead, is the risk already priced in?
Zacks
SYRE and Spyre Ride New IBD Trends in Biotech Drug Design
SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.
Zacks
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
The investment case for Spyre Therapeutics is built around a straightforward but high-risk question: can its broad IBD pipeline produce meaningful clinical proof-of-concept data?
Zacks

Advertisement|Remove ads.